Multifunctional Biomimetic Nanocarriers for Dual-Targeted Immuno-Gene Therapy Against Hepatocellular Carcinoma

Growing evidences have proved that tumors evade recognition and attack by the immune system through immune escape mechanisms, and PDL1/Pbrm1 genes have a strong correlation with poor response or resistance to immune checkpoint blockade (ICB) therapy. Herein, a multifunctional biomimetic nanocarrier (siRNA-CaP@PD1-NVs) is developed, which can not only enhance the cytotoxic activity of immune cells by blocking PD1/PDL1 axis, but also reduce tumor immune escape via Pbrm1/PDL1 gene silencing, leading to a significant improvement in tumor immunosuppressive microenvironment. Consequently, the nanocarrier promotes DC cell maturation, enhances the infiltration and activity of CD8+ T cells, and forms long-term immune memory, which can effectively inhibit tumor growth or even eliminate tumors, and prevent tumor recurrence and metastasis. Overall, this study presents a powerful strategy for co-delivery of siRNA drugs, immune adjuvant, and immune checkpoint inhibitors, and holds great promise for improving the effectiveness and safety of current immunotherapy regimens. A multi-functional biomimetic nanocarrier (siRNA-CaP@PD1-NVs) is developed, capable of simultaneous and efficient delivery of nucleic acid drugs (siRNA), immune adjuvant (CaP), and quasi immune checkpoint inhibitors (PD1-NVs). It can not only enhance the cytotoxic activity of immune cells by blocking PD1/PDL1 axis, but also reduce immune escape via Pbrm1/PDL1 gene silencing, leading to a significant improvement in tumor immuno-gene therapy. image